...
首页> 外文期刊>The Journal of Nuclear Medicine >Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET
【24h】

Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET

机译:重组人促甲状腺激素与甲状腺激素戒断在131I平面全身成像和124I PET中鉴别分化型甲状腺癌的转移

获取原文
获取原文并翻译 | 示例
           

摘要

Various studies have compared the detection of functioning residual thyroid tissue after thyroidectomy using radioiodine whole-body (WB) imaging following preparation of patients with injections of recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone withdrawal (THW). However, metastases may have radiopharmacokinetics different from normal thyroid tissue. The objective of this study was to evaluate these 2 methods of patient preparation for the detection of metastases from differentiated thyroid cancer (DTC) using 131I WB imaging and 124I PET. Methods: A prospective study approved by the institutional review board was conducted at Washington Hospital Center from 2006 to 2010 recruiting patients who had DTC, were suspected of having metastasis from DTC (e.g., elevated thyroglobulin level without thyroglobulin antibodies, positive results on recent fine-needle aspiration, suspected enlarging mass, and abnormal findings suggesting metastasis on a diagnostic study) and were referred for 131I WB dosimetry. All patients subsequently underwent both 131I WB imaging and 124I PET performed using the same preparation. All foci of uptake identified on these scans were categorized in a masked manner by consensus of 2 physicians in the following manner: 1, definite physiologic uptake or artifact; 2, most likely physiologic uptake or artifact; 3, indeterminate; 4, most likely locoregional metastases in the neck bed; 5, most likely distant metastases; or 6, definite distant metastases. Foci categorized as 4, 5, and 6 were considered positive for functioning metastases. Results: Of 40 patients evaluated, 24 patients were prepared with rhTSH and 16 with THW. No statistical difference was noted between the 2 groups for any of the parameters evaluated, including serum thyroglobulin. The percentages of patients with positive foci detected on the rhTSH 131I and THW 131I WB scans were 4% (1/24) and 63% (10/16), respectively (P 0.02). The number of foci detected on the rhTSH 131I and THW 131I WB scans were 2 and 58, respectively (P 0.05). When 124I PET was used for imaging, the percentages of patients with foci detected on the rhTSH and THW scans were 29%(7/24) and 63%(10/16), respectively (P 0.03). The number of foci detected on the rhTSH and THW scans were 17 and 117, respectively (P 0.03). Conclusion: Significantly more foci of metastases of DTC may be identified in patients prepared with THW than in patients prepared with rhTSH.
机译:各种研究比较了准备注射重组人甲状腺刺激激素(rhTSH)和甲状腺激素戒断(THW)的患者准备后,使用放射性碘全身(WB)成像对甲状腺切除术后功能性残留甲状腺组织的检测。但是,转移可能具有不同于正常甲状腺组织的放射药代动力学。这项研究的目的是评估这两种使用131I WB成像和124I PET检测从分化型甲状腺癌(DTC)转移的患者的准备方法。方法:2006年至2010年,在华盛顿医院中心进行了机构审查委员会批准的前瞻性研究,招募患有DTC,怀疑患有DTC转移的患者(例如,无甲状腺球蛋白抗体的甲状腺球蛋白水平升高,近期的阳性结果为针吸,疑似肿块增大和异常结果提示有转移,这在一项诊断研究中得到证实),并转诊接受131I WB剂量测定。随后,所有患者均使用相同的制剂进行了131I WB成像和124I PET成像。两位医生的共识以掩盖的方式将这些扫描中发现的所有摄取灶点归类为以下几种:1,确定的生理摄取或伪影; 2,最可能的生理摄取或伪影; 3,不确定; 4,最有可能发生在颈部床上的局部转移; 5,最可能的远处转移;或6,明确的远处转移。分类为4、5和6的病灶被认为对转移灶呈阳性。结果:在评估的40例患者中,有24例准备了rhTSH,16例准备了THW。对于两组评估的参数,包括血清甲状腺球蛋白,两组之间均未发现统计学差异。在rhTSH 131I和THW 131I WB扫描中检出阳性灶的患者百分比分别为4%(1/24)和63%(10/16)(P <0.02)。在rhTSH 131I和THW 131I WB扫描中检测到的病灶数分别为2和58(P <0.05)。当使用124I PET进行成像时,在rhTSH和THW扫描中发现病灶的患者百分比分别为29%(7/24)和63%(10/16)(P <0.03)。在rhTSH和THW扫描中检测到的病灶数分别为17和117(P <0.03)。结论:相比使用rhTSH的患者,在THW的患者中可以发现更多的DTC转移灶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号